26/06/2022
S&K is a biopharmaceutical company founded in July 2020.
S&K develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate drug targets such as TLRs, TNF-a, NLRP3, IL-23, IL-17, and IL-18. We employ cutting-edge science and technology (artificial intelligence, machine learning, and molecular dynamics simulation), to address some of society's most challenging healthcare issues.
In our quest to find new therapeutic candidates for autoimmune and inflammatory diseases such as systemic lupus erythematosus, psoriasis, rheumatoid arthritis, Alzheimer's, and diabetes.
Our mission is to develop breakthrough safe and effective therapies for unmet needs in autoimmune diseases.
